1-2 of 2
Xiaoyun Nicole Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor-Agnostic Approvals: Insights and Practical Considerations

Chengxing Cindy Lu, Robert A. Beckman, Xiaoyun Nicole Li, Weidong Zhang, Qi Jiang, Olga Marchenko, Zhiping Sun, Hong Tian, Jingjing Ye, Shuai Sammy Yuan, Godwin Yung, on behalf of the Master Protocol subteam of the Statistical Methods in Oncology Scientific Working Group, Biopharmaceutical Session, American Statistical Association
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 480–488.
https://doi.org/10.1158/1078-0432.CCR-23-1340
Published: 01 February 2024
View article titled, Tumor-Agnostic Approvals: Insights and Practical Considerations
Open the PDF for Tumor-Agnostic Approvals: Insights and Practical Considerations in another window
Journal Articles

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, S. Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Nicole Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, Manfred Lehnert, Robert Iannone, Anthony W. Tolcher
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (19): 4286–4293.
https://doi.org/10.1158/1078-0432.CCR-14-2607
Published: 30 September 2015
View article titled, Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data